{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:29:19Z","timestamp":1718238559155},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,12]]},"DOI":"10.7759\/cureus.62212","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T07:57:27Z","timestamp":1718179047000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rare Case of Pleural Epithelioid Mesothelioma With a Prominent Myxoid Stroma Reported With Morphology, Fluorescent In Situ Hybridization, and Ultrastructural Findings"],"prefix":"10.7759","author":[{"given":"Hiroshi","family":"Sonobe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Omote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Habara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Washio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Yamazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176342","article-title":"Genomics and functional genomics of malignant pleural mesothelioma","volume":"21","author":"Cakiroglu E","year":"2020","unstructured":"Cakiroglu E, Senturk S. Genomics and functional genomics of malignant pleural mesothelioma. Int J Mol Sci. 2020, 21:6342. 10.3390\/ijms21176342","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5652-y","article-title":"CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure","volume":"19","author":"Kettunen E","year":"2019","unstructured":"Kettunen E, Savukoski S, Salmenkivi K, et al.. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure. BMC Cancer. 2019, 19:507. 10.1186\/s12885-019-5652-y","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant mesothelioma and its non-asbestos causes","volume":"142","author":"Attanoos RL","year":"2018","unstructured":"Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 2018, 142:753-60. 10.5858\/arpa.2017-0365-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis WD","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, et al.. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015, 10:1243-60. 10.1097\/JTO.0000000000000630","journal-title":"J Thorac Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung","volume":"13","author":"Tsao AS","year":"2018","unstructured":"Tsao AS, Lindwasser OW, Adjei AA, et al.. Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung. J Thorac Oncol. 2018, 13:1655-67. 10.1016\/j.jtho.2018.08.2036","journal-title":"J Thorac Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-203993","article-title":"Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma","volume":"70","author":"Alchami FS","year":"2017","unstructured":"Alchami FS, Attanoos RL, Bamber AR. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma. J Clin Pathol. 2017, 70:179-82. 10.1136\/jclinpath-2016-203993","journal-title":"J Clin Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-005-0035-y","article-title":"Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases","volume":"447","author":"Shia J","year":"2005","unstructured":"Shia J, Qin J, Erlandson RA, et al.. Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases. Virchows Arch. 2005, 447:828-34. 10.1007\/s00428-005-0035-y","journal-title":"Virchows Arch"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter JL","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F, et al.. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol. 2022, 17:608-22. 10.1016\/j.jtho.2021.12.014","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.002","article-title":"Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal","volume":"13","author":"Pelosi G","year":"2018","unstructured":"Pelosi G, Papotti M, Righi L, et al.. Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal. J Thorac Oncol. 2018, 13:1750-61. 10.1016\/j.jtho.2018.07.002","journal-title":"J Thorac Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen LE","year":"2018","unstructured":"Rosen LE, Karrison T, Ananthanarayanan V, et al.. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018, 31:598-606. 10.1038\/modpathol.2017.170","journal-title":"Mod Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti M","year":"2015","unstructured":"Cigognetti M, Lonardi S, Fisogni S, et al.. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015, 28:1043-57. 10.1038\/modpathol.2015.65","journal-title":"Mod Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel DB","year":"2020","unstructured":"Chapel DB, Schulte JJ, Berg K, et al.. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol. 2020, 33:245-54. 10.1038\/s41379-019-0310-0","journal-title":"Mod Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPT94JVWIHBKRD","article-title":"Diagnostic usefulness of p16\/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis","volume":"139","author":"Wu D","year":"2013","unstructured":"Wu D, Hiroshima K, Matsumoto S, et al.. Diagnostic usefulness of p16\/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013, 139:39-46. 10.1309\/AJCPT94JVWIHBKRD","journal-title":"Am J Clin Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo G","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, et al.. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015, 75:264-9. 10.1158\/0008-5472.CAN-14-1008","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang M","year":"2021","unstructured":"Zhang M, Luo JL, Sun Q, et al.. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat Commun. 2021, 12:1751. 10.1038\/s41467-021-21798-w","journal-title":"Nat Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00709-4","article-title":"Roles and mechanisms of BAP1 deubiquitinase in tumor suppression","volume":"28","author":"Masclef L","year":"2021","unstructured":"Masclef L, Ahmed O, Estavoyer B, Larriv\u00e9e B, Labrecque N, Nijnik A, Affar EB. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ. 2021, 28:606-25. 10.1038\/s41418-020-00709-4","journal-title":"Cell Death Differ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg KB","year":"2018","unstructured":"Berg KB, Dacic S, Miller C, Cheung S, Churg A. Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas. Arch Pathol Lab Med. 2018, 142:1549-53. 10.5858\/arpa.2018-0273-OA","journal-title":"Arch Pathol Lab Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida T","year":"2017","unstructured":"Hida T, Hamasaki M, Matsumoto S, et al.. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer. 2017, 104:98-105. 10.1016\/j.lungcan.2016.12.017","journal-title":"Lung Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.11.013","article-title":"Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: a multi-institutional study","volume":"175","author":"Sa-Ngiamwibool P","year":"2023","unstructured":"Sa-Ngiamwibool P, Hamasaki M, Kinoshita Y, et al.. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: a multi-institutional study. Lung Cancer. 2023, 175:27-35. 10.1016\/j.lungcan.2022.11.013","journal-title":"Lung Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j j.rmcr.2021.101381","article-title":"A patient with epithelioid pleural mesothelioma (myxoid variant) who survived for a long period without treatment","volume":"33","author":"Mizuhashi K","year":"2021","unstructured":"Mizuhashi K, Okamoto K, Kishimoto T. A patient with epithelioid pleural mesothelioma (myxoid variant) who survived for a long period without treatment. Respir Med Case Rep. 2021, 33:101381-10. 10.1016\/j j.rmcr.2021.101381","journal-title":"Respir Med Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/255263-a-rare-case-of-pleural-epithelioid-mesothelioma-with-a-prominent-myxoid-stroma-reported-with-morphology-fluorescent-in-situ-hybridization-and-ultrastructural-findings","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T07:57:30Z","timestamp":1718179050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/255263-a-rare-case-of-pleural-epithelioid-mesothelioma-with-a-prominent-myxoid-stroma-reported-with-morphology-fluorescent-in-situ-hybridization-and-ultrastructural-findings"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.62212","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}